

---

## Fluoguide Q4 2023 - Bright prospects

Redeye comments on Fluoguide's Q4 2023 report, with the company having recently communicated a strategy update. We believe the company's new strategy is value-accretive overall, though it likely delays a potential market approval for FG001 by c6-12 months. We do some housekeeping in our model and leave our estimates and valuation largely unchanged.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. [www.redeye.se/](http://www.redeye.se/)

### Attachments

---

[Fluoguide Q4 2023 - Bright prospects](#)